Prime Medicine
PRME

Prime Medicine (PRME) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Chardan CapitalMaintainedBuy$7.00Aug 25, 2026
BMO CapitalInitiated CoverageOutperform$9.00Aug 19, 2026
HC Wainwright & Co.MaintainedBuy$8.00Aug 10, 2026
HC Wainwright & Co.UpgradedNeutral → Buy$8.00Jun 29, 2026
OppenheimerInitiated CoverageOutperform$11.00Mar 12, 2026
LifeSci CapitalInitiated CoverageOutperform$6.00Dec 23, 2025
CitigroupMaintainedNeutral$4.25 from $5.00Nov 11, 2025
Chardan CapitalMaintainedBuy$9.00 from $10.00Nov 10, 2025
Chardan CapitalMaintainedBuy$10.00 from $12.00Aug 8, 2025
CitigroupDowngradedBuy → Neutral$1.50 from $10.00May 27, 2025
HC Wainwright & Co.DowngradedBuy → NeutralMay 20, 2025
JP MorganDowngradedOverweight → NeutralMay 20, 2025
JMP SecuritiesMaintainedMarket Outperform$6.00 from $10.00May 20, 2025
Chardan CapitalMaintainedBuy$12.00 from $16.00May 19, 2025
Chardan CapitalMaintainedBuy$16.00 from $15.00Mar 20, 2025
HC Wainwright & Co.MaintainedBuy$10.00Mar 19, 2025
Citizens Capital MarketsMaintainedMarket Outperform$10.00Mar 4, 2025
Chardan CapitalMaintainedBuy$15.00Mar 3, 2025
HC Wainwright & Co.MaintainedBuy$10.00Mar 3, 2025
JMP SecuritiesInitiated CoverageMarket Outperform$10.00Dec 10, 2024

Frequently asked questions

  • What is the latest analyst rating on PRME?

    On Aug 25, 2026, Chardan Capital maintained Prime Medicine at Buy with a price target of $7.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.